We are excited to look for donors for the first study we will be sponsoring in 2021. This double-blind, placebo-controlled MDMA study will be conducted by the University of Otago in conjunction with the University of Auckland. We believe this study will be breakthrough for many terminal cancer sufferers and dovetails nicely with recent reports from MAPS(see here https://maps.org/news/update ) .
Effect of MDMA-assisted therapy on Mood and Anxiety symptoms in patients with advanced-stage Cancer Study
This study will seek to answer the question of whether MDMA-assisted therapy is a safe and potentially translatable therapy for treatment of depression and anxiety in the Palliative care population. This patient population is vulnerable to depression and anxiety, arguably the two most difficult to treat medical conditions with the greatest impact on quality of life and quality of death. Pain, nausea, fatigue, cachexia are all physical symptoms intricately linked to and exacerbated by pathological mental states. Current treatment paradigms are inadequate due, in part, to the lack of access for patients to psychotherapeutic resources and a degree of therapeutic nihlism on the part of clinicians as a result. By providing a new treatment that potentially accelerates the psychotherapeutic process we would be providing a transformative and, potentially, more accessible approach to relieving the mental suffering of patients facing their mortality.
Read more about this study at Trypt.am: https://trypt.am/entheogen/mdma/ACTRN12619001334190p
If you have any further questions about this study, please contact us. Otherwise, please donate below to help cancer sufferers improve their quality of life:
You may donate directly to our charity bank account below. This is a BNZ account, so transfers from other banks may take longer:
Click on the image below to donate via paypal.